Sharekhan's research report on Sun Pharmaceutical Industries
Sun Pharma’s Q2FY2020 results are in line with estimates. Staggered penetration of specialty portfolio, higher specialty promotional spends, increasing R&D, and continued pricing issues in the U.S. are likely to be the key challenge for earnings growth We expect the company to report sales and profit CAGR of 14% and 22%, respectively, over the next two years.
Outlook
We maintain Hold rating on Sun Pharma with a revised PT of Rs 460.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
Read More
